Evernimicin

Drug Profile

Evernimicin

Alternative Names: SCH 27899; Ziracin

Latest Information Update: 21 Feb 2002

Price : $50

At a glance

  • Originator Schering-Plough
  • Class Aminoglycosides; Antibacterials; Peptide antibiotics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 21 Feb 2002 A clinical study has been added to the pharmacokinetics section
  • 10 May 2000 Schering-Plough has discontinued the development of everninomycin in phase III
  • 10 May 2000 Discontinued-Unspecified phase in Bacterial infections in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top